Slowing of progression and inducing the regression of atherosclerosis with medical therapy have been shown to be associated with an extensive reduction in risk of cardiovascular events.
Introduction
Drug discovery and development follow a complex and long pathway that often does not lead to a commercially viable product. As the cost of drug development burgeoned to prohibitive levels over the past few decades, investigators and industry have looked for ways to curb expenses and increase efficiency minimizing possible failures. The development of new drugs to treat atherosclerosis is often met with the requirement to conduct lengthy outcome trials at extraordinary costs. To limit the possibility of failing to attain the desired outcome after having conducted a phase-3 trial, investigators have utilized surrogate targets that provide information on the burden and composition of atherosclerotic plaques. 1, 2, 3 Particularly challenging is the development of drugs for rare diseases, where conducting randomized outcome trials is hampered by the limited number of patients affected by the condition under study. In this light, atherosclerosis imaging has provided intermediate goals to test effectiveness of novel treatments. 4, 5, 6 There are indisputable advantages in using imaging endpoints. For example, while in mortality and morbidity trials the endpoint is only provided by patients who experience an event, in trials based on imaging biomarkers the endpoint is provided by every patient. This increases the statistical power of the study, thus leading to a reduction in the number of patients compared to event driven trials (tens or hundreds rather than thousands of subjects) and shorter follow-ups (6-24 months rather than 4-6 years). Given its potential impact on drug development, atherosclerosis imaging has been the focus of intense debate and growing interest among scientists, industry and regulators alike. In this paper we review the state of the art of magnetic resonance (MR) for vascular imaging, with a specific focus on its implementation in the process of drug development. Magnetic resonance imaging can provide information on the location, extent and composition of atheromatous plaques in peripheral arterial beds and has been used in numerous trials to study regression of atherosclerosis.
However, to date MRI has demonstrated no utility to image coronary artery atherosclerotic plaques.
Imaging biomarkers and their utility
Atherosclerosis is mostly a silent disease and autopsy studies revealed that it is already present in youth. 7 Because of its silent development its first manifestation is often a sudden and unheralded event. This induced scientists and physicians to develop a number of algorithms to estimate risk of events and stimulated the development of a large array of biomarkers and imaging modalities to assess the presence of atherosclerosis and its progression. relationship between treatment and a particular (beneficial) outcome." Hence the acknowledgement that there is an "ideal" and "preferable" way to proceed, but it may not be always possible.
Three questions should be considered; (1) can a study with a "highly preferred" endpoint be conducted? ("highly preferred" might mean preferred by the regulators, and/or an obvious clinical endpoint); (2) is such an endpoint absolutely necessary in order to determine the clinical value of a therapy? and (3) is it actually desirable to use the "highly preferred" endpoint, or would a more efficient trial better serve the public health interest? To this end, intravascular ultrasound (IVUS) and MRI studies offer the opportunity to pursue more efficient endpoints (i.e.
smaller trial sizes, with shorter duration and good level of assurance over the results) than more traditional "established clinical endpoints". At the same time they may provide enough information to inform a decision to pursue larger clinical trials or whether such trials should be stopped. Despite its success, QCA is limited by its invasive nature, the need to use iodinated contrast media and the exposure of patients to ionizing radiation and is therefore not fit for population studies. This stimulated and facilitated the development of non-invasive imaging modalities to detect atherosclerosis and study its progression. Pignoli et al 19 were the first to demonstrate that the thickness of the arterial wall comprising the intima and media layers (IMT) of the femoral arteries was closely associated with atherosclerosis of the aorta. Given the greater ease and convenience of measurement, carotid IMT (cIMT) quickly replaced measurement of femoral IMT (Figure 1) . Several epidemiological studies later showed that cIMT is an independent predictor of stroke and cardiovascular events in the general population. 20 As proof of concept, over the last two decades, many investigators have employed cIMT as primary endpoint in clinical trials designed to identify populations at risk and assess the effectiveness of anti-atherosclerotic drugs.
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Although successfully employed to study the effect of cardiovascular drugs in large population trials, 22, 23, 24 in several cases randomized clinical trials using the same drugs that regressed cIMT gave inconclusive or negative results. cIMT has several distinct disadvantages when used to evaluate the efficacy of drugs on regression and progression of atherosclerotic plaques. The number of patients to demonstrate the efficacy of interventions on plaque size and composition. 31 These characteristics of high-resolution MRI imaging are particularly desirable when research is focused on mechanistic plaque studies of innovative compounds in patients with rare diseases who are difficult to discover and enroll in clinical trials.
As indicated in the previous paragraphs, the value of surrogate biomarkers is embedded in their ability to identify a disease state and its change prior to the outbreak of symptomatic disease.
These properties are crucial when studying rare diseases, as the population size is limited and may be geographically widespread. According to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) group, the average prevalence threshold for a rare disease ranges from 5 to 76 cases/100,000 people, with a global average of 40 cases/100,000 people. 32 With such a small prevalence, the inclusion of thousands (or even only hundreds) of patients in a study becomes virtually impossible, thus making essential the identification of sensitive imaging biomarkers that allow the designing of studies with sufficient statistical power despite the availability of only a few dozens of patients.
Magnetic Resonance Imaging in Clinical Trials
Magnetic Resonance Imaging (MRI) has become one of the leading non-invasive in-vivo imaging modalities for quantification and characterization of atherosclerosis. Like ultrasound, MRI does not expose patients to ionizing radiation and can be repeated as often as required: it enables measurement of plaque burden (area and volume), luminal narrowing and plaque characteristics. 33, 34 Additionally, with MRI it is possible to assess the thickness of the fibrouscap covering a plaque 35 and the extent of the lipid-rich necrotic core (LRNC), 36 ( Figure 2 ) as well as adventitial neovascularization 37 and intra-plaque haemorrhage. 30 Image acquisition in MRI requires a high degree of expertise although most measurements are fairly operator independent. Additionally, MRI imaging provides multi-planar 3D data with sub-millimeter spatial resolution. 30 Most of the MR vascular imaging work has been performed on 1.5T (Tesla) MR scanners. However, more modern imaging at 3T provides a higher signal-to-noise ratio with better resolution compared to 1.5T. The imaging protocols have matured and sequences have been optimized enough at 3T that it is recommendable that future clinical studies be conducted with 3T scanners.
The superior reproducibility of MR resulted in the ability to conduct limited size studies to demonstrate a proof of concept. In fact, several studies have shown that significant changes in carotid atherosclerosis (area or volume) can be detected with moderate sample sizes (less than 40 patients per arm) within the first months or year of intervention ( This has been used to detect both plaque rupture and intra-plaque haemorrhage in the carotid arteries. In particular, high signal can be observed in the culprit plaques of patients who have suffered a recent stroke. 47, 48 In a recent study the presence of such high-intensity Alternative MRI techniques have also been explored as efficacy end-points in clinical trials.
Ultra-small particles of iron oxide (USPIO) have superparamagnetic properties on T2* weighted sequences. They have been used to measure vascular inflammation, since these particles are removed from the circulation by the reticuloendothelial system and accumulate in macrophages present in atherosclerotic plaques. In the ATHEROMA study 50 the investigators randomized 47 patients with carotid stenosis >40% and high USPIO uptake on baseline scans, to either 10mg or 80mg of Atorvastatin daily for 12 weeks. A significant decrease in the carotid plaque USPIO uptake was observed in the high-dose cohort but not the low-dose group.
Taken together, these data show that MRI allows an accurate assessment of the effects of treatment on atherosclerotic plaque burden and composition with very small sample sizes and during short follow-up times. These characteristics make MRI a very efficient tool for a variety of clinical trials but especially those involving patients affected by rare diseases for which large sample sizes are unavailable. The ability of MRI to detect changes in atherosclerosis burden in rare diseases will be tested again in the recently announced TANGO trial (https://clinicaltrials.gov/ct2/show/NCT02697136?term=TANGO&rank=6). In this phase III multi-center trial, 30 patients with familial primary hypoalphalipoproteinemia on optimal lipid lowering medical therapy, will be randomized to treatment with an HDL mimetic compound or placebo. The primary end-point of the trial will be change in carotid mean plaque area measured by 3T MRI after 24 weeks of treatment. Given the small number of individuals recruitable with such a rare disease and the difficulty to assess efficacy, MR appears to be the perfect tool to provide the answer to this difficult question.
In summary, in a substantial and growing number of cases the scientific, clinical and pharmaceutical communities have embraced non-invasive cardiovascular imaging to evaluate changes in human atherosclerosis as a desirable method to assess therapeutic efficacy of novel and innovative drugs. Development of pharmaceutical agents designed to slow or prevent atherosclerotic disease and improve cardiovascular health can benefit from these imaging markers. The available evidence shows that MRI allows an accurate assessment of the effects of treatment on atherosclerotic plaque burden and composition with very small sample sizes and short follow-up times. Like cIMT and other imaging modalities, however, to date there have been no reports of prospective clinical studies linking MRI-measured atherosclerosis with incident clinical events, and these data will need to be actively collected in future trials. 
